EXPERIMENTAL RESEARCH
Pretreatment with obestatin inhibits the development of acetic acid-induced colitis in rats
 
More details
Hide details
Submission date: 2015-11-02
Final revision date: 2016-01-08
Acceptance date: 2016-01-22
Online publication date: 2016-03-23
Publication date: 2018-06-19
 
Arch Med Sci 2018;14(4):920–929
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Obestatin is a 23-amino acid peptide derived from proghrelin, a common prohormone for ghrelin and obestatin. Previous studies have shown that obestatin exhibits some protective and therapeutic effects in the pancreas and stomach. The aim of this study was to examine the effect of pretreatment with obestatin on the development of acetic acid-induced colitis.

Material and methods:
Studies were performed on Wistar rats. Before induction of colitis, rats were treated intraperitoneally with saline or obestatin, administered twice at a dose of 4, 8 or 16 nmol/kg/dose. The first dose of saline or obestatin was administered 8 h before the induction of colitis, the second one 7 h after the first dose. Colitis was induced by enema with 1 ml of 4% acetic acid solution. The severity of colitis was assessed 1 or 24 h after administration of enema.

Results:
Pretreatment with obestatin administered at a dose of 8 or 16 nmol/kg/dose significantly reduced the area of mucosal damage evoked by enema with acetic acid (p < 0.05). This effect was accompanied by an improvement of mucosal blood flow and DNA synthesis in the colon. Moreover, obestatin administered at a dose of 8 or 16 nmol/kg/dose significantly reduced mucosal concentration of IL-1β and activity of myeloperoxidase (p < 0.05).

Conclusions:
Pretreatment with obestatin exhibited a protective effect in the colon, leading to a reduction of colonic damage in acetic acid-induced colitis. This effect was associated with an improvement of mucosal blood flow, an increase in mucosal cell proliferation, and a decrease in local inflammation.

eISSN:1896-9151
ISSN:1734-1922